Medical Marijuana Research Act
USA117th CongressHR-5657| House
| Updated: 4/5/2022
Earl Blumenauer
Democratic Representative
Oregon
Cosponsors (11)
Health Subcommittee, Judiciary Committee, Energy and Commerce Committee, Budget Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Medical Marijuana Research Act This bill establishes a new, separate registration process to facilitate medical marijuana research. Specifically, it directs the Drug Enforcement Administration to register (1) practitioners to conduct medical marijuana research, and (2) manufacturers and distributors to supply marijuana for such research. Additionally, the Department of Health and Human Services must continue to produce marijuana through the National Institute on Drug Abuse Drug Supply Program and implement a specialized process for supplying marijuana products available through state-authorized marijuana programs to researchers until manufacturers and distributors can provide a sufficient supply of marijuana for medical research.
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsor introductory remarks on measure. (CR E1126)
Referred to the Subcommittee on Health.
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
Considered under suspension of the rules. (consideration: CR H4136-4140)
DEBATE - The House proceeded with forty minutes of debate on H.R. 5657.
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Considered as unfinished business. (consideration: CR H4144-4145)
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 343 - 75 (Roll no. 108). (text: CR H4136-4138)
View VoteMotion to reconsider laid on the table Agreed to without objection.
Received in the Senate.
Health
Administrative law and regulatory proceduresAlternative treatmentsDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationDrug therapyDrug trafficking and controlled substancesFood and Drug Administration (FDA)Health personnelLicensing and registrationsMedical researchResearch administration and funding
Medical Marijuana Research Act
USA117th CongressHR-5657| House
| Updated: 4/5/2022
Medical Marijuana Research Act This bill establishes a new, separate registration process to facilitate medical marijuana research. Specifically, it directs the Drug Enforcement Administration to register (1) practitioners to conduct medical marijuana research, and (2) manufacturers and distributors to supply marijuana for such research. Additionally, the Department of Health and Human Services must continue to produce marijuana through the National Institute on Drug Abuse Drug Supply Program and implement a specialized process for supplying marijuana products available through state-authorized marijuana programs to researchers until manufacturers and distributors can provide a sufficient supply of marijuana for medical research.
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsor introductory remarks on measure. (CR E1126)
Referred to the Subcommittee on Health.
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
Considered under suspension of the rules. (consideration: CR H4136-4140)
DEBATE - The House proceeded with forty minutes of debate on H.R. 5657.
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Considered as unfinished business. (consideration: CR H4144-4145)
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 343 - 75 (Roll no. 108). (text: CR H4136-4138)
View VoteMotion to reconsider laid on the table Agreed to without objection.
Received in the Senate.
Earl Blumenauer
Democratic Representative
Oregon
Cosponsors (11)
Health Subcommittee, Judiciary Committee, Energy and Commerce Committee, Budget Committee
Health
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Administrative law and regulatory proceduresAlternative treatmentsDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationDrug therapyDrug trafficking and controlled substancesFood and Drug Administration (FDA)Health personnelLicensing and registrationsMedical researchResearch administration and funding